LIANYOTCPharmaceutical PreparationsFiscal year ends December 31

LianBio

Financials through Q3 FY2023, quarter ended Sep 30, 2023Last filing: 10-Q on Nov 13, 2023

$0.06+0.01 (+15.10%)

Close on Oct 19, 2026

Market cap: $6.29M
P/E (TTM): –
Dividend yield: –

LianBio balance sheet

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31
Cash & Equivalents	79	248	254	43
Short-Term Investments	223	155	0	–
Cash & Short-Term Investments	302	383	254	43
Prepaid Expenses & Other	8.64	10	2.40	–
Total Current Assets	313	400	277	–
Property, Plant & Equipment	3.12	1.88	0.82	–
Gross Property, Plant & Equipment	4.66	2.49	0.90	–
Accumulated Depreciation	-1.55	-0.61	-0.08	–
Operating Lease Right-of-Use Assets	3.98	4.76	1.71	–
Other Long-Term Assets	0.02	0.05	0.01	–
Total Assets	320	426	279	–
Accounts Payable	1.45	3.23	4.33	–
Accrued Expenses	20	9.98	1.00	–
Current Portion of Leases	1.85	1.13	0.54	–
Other Current Liabilities	0.49	0.76	0.36	–
Total Current Liabilities	24	15	6.23	–
Long-Term Leases	2.49	3.71	1.34	–
Operating Lease Liabilities	4.34	4.83	1.88	–
Other Long-Term Liabilities	0.21	0.21	0	–
Total Liabilities	26	39	28	–
Preferred Stock	–	–	350	–
Common Stock	0.00	0.00	0	–
Additional Paid-In Capital	732	713	31	–
Retained Earnings	-471	-360	-164	–
Comprehensive Income & Other	-2.08	0.53	-0.04	–
Shareholders' Equity	260	354	-133	–
Noncontrolling Interest	34	34	35	–
Total Equity	294	387	-98	-15
Total Liabilities & Equity	320	426	279	–
Shares Outstanding(shares)	107	107	20	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Sep 30, 2023

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2022: -36.0%

Financial strength

Current ratio: 10.06
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 403.7%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 0.03
Dividend yield: –